Synthon has entered into a global pharma partners license agreement with Amgen and Watson Pharmaceuticals, for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin, which is currently approved for treatment of breast cancer and gastric cancer.
Under this pharma partners agreement, Watson has acquired the license to the biosimilar program and has contributed it to the Amgen/Watson biosimilars collaboration.
Amgen and Watson will assume responsibility for all future development work worldwide, including Phase III clinical trials, as well as global manufacturing and commercialization.
Synthon will provide transitional support as set forth in the pharma partners agreement.
The deal entitles Synthon to an initial payment and potentially a milestone fee and royalties on net sales.
Synthon will also receive compensation for its transitional support activities under this pharma partners agreement.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Amgen
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity